Nuvation Bio Inc. (NYSE:NUVB) is one of the the best high short interest stocks with the greatest upside potential. On Jan. 27, Truist raised its price target on Nuvation Bio to $13 from $11 and maintained a buy rating, citing strong early performance from the Ibtrozi franchise as part of a Q4 2025 earnings forecast for the biotech sector. Despite seasonal challenges, the company saw stronger-than-expected market uptake, positioning Ibtrozi as the preferred ROS1 agent over its competitors.

Earlier on January 21, RBC Capital analyst Leonid Timashev raised his price target on Nuvation Bio to $12 from $9 with an outperform rating. This adjustment has occurred after meetings with management teams, which have led the firm to update its financial models for several companies in the biotech sector.

On January 12, HC Wainwright cut their price target on Nuvation Bio Inc. (NYSE:NUVB) to $17 from $18, maintaining a buy rating. The company noted that the company’s fourth quarter Ibtrozi product preliminary net revenue of ~$15.7 million was in line with its expectations.

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company developing therapeutic candidates for oncology.

While we recognize NUVB’s potential as an investment, we believe certain AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 30 stocks that should double in 3 years i 11 Hidden AI Stocks to Buy Right Now.

Disclosure: no. This article is originally published in Monkey Insider.